SPHRYStarpharma Holdings Ltd.

About Starpharma Holdings Ltd. (SPHRY)

Starpharma Holdings Ltd. (SPHRY) is a Biotechnology company headquartered in Abbotsford, VA, Australia whose shares trade over-the-counter on the OTCQX tier.

Starpharma Holdings Limited (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Products and services

Starpharma has developed an innovative drug delivery platform using proprietary dendrimer nanoparticles, known as DEP®, to enhance the efficacy and tolerability of pharmaceutical products. Starpharma utilizes the DEP® technology for its own pipeline of assets and collaborates with partners to apply this technology to their drug discovery programs and pipeline assets. Starpharma’s portfolio of dendrimer-based products includes clinical-stage oncology assets, preclinical radiopharmaceuticals and antibody-drug conjugate (ADC) assets, research collaborations, and commercially marketed over-the-counter (OTC) products.

SPHRY key facts

Ticker symbol

SPHRY

Market tier

OTCQX

Sector

Healthcare

Industry

Biotechnology

Headquarters

Abbotsford, VA, Australia

Country of incorporation

AU

Year of incorporation

1997

Employees

40

Estimated market cap

$23.85M (as of May 14, 2025)

Shares outstanding

418,224,781

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Quarterly Report (Mar 31, 2025)

Starpharma Holdings Ltd. leadership

• Cherly Maley — CEO
• Justin Cahill — CFO, Company Secretary Manager
• Andrew William Bond — Chief Accounting Officer

Explore more: Biotechnology stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with S